Literature DB >> 19386971

Frequency of isolated hepatitis B core antibody in HIV-hepatitis C virus co-infected individuals.

A Ramezani1, M Mohraz, A Aghakhani, M Banifazl, A Eslamifar, A Khadem-Sadegh, A A Velayati.   

Abstract

Association between isolated hepatitis B core antibody (anti-HBc) and hepatitis C virus (HCV) infection has been noted in HIV-infected individuals. This study describes the frequency of isolated anti-HBc and its possible value for the detection of HBV-DNA in HIV-infected patients with or without HCV co-infection. Ninety-two HIV-infected patients were enrolled in the study. Hepatitis B surface antigen (HBs Ag), anti-HBs, anti-HBc, anti-HCV, HIV viral load and CD4 count were tested in all subjects. Then we compared 63 subjects with HIV-HCV co-infection with 29 subjects with HIV infection alone regarding isolated anti-HBc (HBs Ag negative, anti-HBs negative and anti-HBc positive). The presence of HBV-DNA was determined by real-time polymerase chain reaction in serum samples of patients with isolated anti-HBc. Of 63 anti-HCV-positive patients, 18 subjects (28.6%, 95% [confidence interval] CI: 22.6-34.6%), and of 29 anti-HCV-negative patients, five subjects (17.2%, 95% CI: 11.5-22.9%) had isolated anti-HBc. HBV-DNA was detectable in three of 18 anti-HCV-positive patients (16.7%, 95% CI: 9.7-23.7%) and none of the anti-HCV-negative patients with isolated anti-HBc. Our study showed that individuals co-infected with HIV and HCV were more likely to have isolated anti-HBc than subjects with HIV alone. This investigation also demonstrates that the presence of isolated anti-HBc in HIV-HCV-infected individuals may reflect occult HBV infection in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19386971     DOI: 10.1258/ijsa.2008.008377

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  8 in total

1.  Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption.

Authors:  S Bagaglio; L Porrino; A Lazzarin; G Morsica
Journal:  Infection       Date:  2010-06-09       Impact factor: 3.553

2.  Hepatitis C Virus Coinfection in People With Human Immunodeficiency Virus in Iran: A Systematic Review and Meta-Analysis.

Authors:  Seyedeh-Kiana Razavi-Amoli; Abbas Alipour
Journal:  Open Forum Infect Dis       Date:  2022-09-21       Impact factor: 4.423

Review 3.  Clinical impact of occult hepatitis B virus infection in immunosuppressed patients.

Authors:  Evangelista Sagnelli; Mariantonietta Pisaturo; Salvatore Martini; Pietro Filippini; Caterina Sagnelli; Nicola Coppola
Journal:  World J Hepatol       Date:  2014-06-27

4.  Occult hepatitis B virus infection: A major concern in HIV-infected patients: Occult HBV in HIV.

Authors:  Amitis Ramezani; Mohammad Banifazl; Minoo Mohraz; Mehrnaz Rasoolinejad; Arezoo Aghakhani
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

Review 5.  Prevalence of Hepatitis B Co-Infection among HIV Positive Patients: Narrative Review Article.

Authors:  Azam Askari; Hamid Hakimi; Behzad Nasiri Ahmadabadi; Gholamhossein Hassanshahi; Mohammad Kazemi Arababadi
Journal:  Iran J Public Health       Date:  2014-06       Impact factor: 1.429

Review 6.  The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses.

Authors:  Sarwat Mahmud; Vajiheh Akbarzadeh; Laith J Abu-Raddad
Journal:  Sci Rep       Date:  2018-01-09       Impact factor: 4.379

7.  Occult hepatitis B infection in different high risk patients.

Authors:  Amitis Ramezani; Mohammad Banifazl; Ali Eslamifar; Masoomeh Sofian; Arezoo Aghakhani
Journal:  Hepat Mon       Date:  2012-07-30       Impact factor: 0.660

8.  Prevalence of occult hepatitis B virus infection in a cohort of HIV-positive patients resident in Sicily, Italy.

Authors:  Fabio Tramuto; Carmelo Massimo Maida; Giuseppina M E Colomba; Paola Di Carlo; Francesco Vitale
Journal:  Biomed Res Int       Date:  2013-08-26       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.